Omalizumab (humanized, monoclonal antibody that binds to circulating IgE molecules) was the first approved treatment for patients with allergic asthma, followed by treatments targeting the IL-5 pathway: mepolizumab (monoclonal antibody that binds to IL-5), reslizumab (also a monoclonal antibody that binds specifically to IL-5), and benralizumab (monoclonal antibody that binds directly to the IL-5-receptorα on eosinophils) [17]. The gene discussed is IL5; the disease is allergic asthma.